APO Research
Talk to an analyst

APO RESEARCH · REPORT

Virus like Particle (VLP) Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Virus like Particle (VLP) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025199 pages

Choose your research edition.

Industry ResearchVirus like Particle (VLP) Vaccines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Virus like Particle (VLP) Vaccines Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Virus like Particle (VLP) Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Virus like Particle (VLP) Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Virus like Particle (VLP) Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Virus like Particle (VLP) Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Virus like Particle (VLP) Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Virus like Particle (VLP) Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Virus like Particle (VLP) Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Virus like Particle (VLP) Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Virus like Particle (VLP) Vaccines Segment by Company

WuXi Biologics

Junshi Biosciences

Luye Pharma Group

Chengdu Kanghua Biological Products Co., Ltd.

Shanghai Bovax Biotechnology Co., Ltd.

VBI Vaccines Inc

Premas Biotech

Creative Diagnostics

Creative Biostructure

Coriolis

Charles River Laboratories

BioAgilytix

AstraZeneca Group (Icosavax)

Virus like Particle (VLP) Vaccines Segment by Type

Prophylactic Vaccine

Therapeutic Vaccine

Virus like Particle (VLP) Vaccines Segment by Application

Human Papillomavirus (HPV)

Hepatitis E Virus (HEV)

Hepatitis B Virus (HBV)

Other

Virus like Particle (VLP) Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Virus like Particle (VLP) Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Virus like Particle (VLP) Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Virus like Particle (VLP) Vaccines Industry Trends Table 2. Virus like Particle (VLP) Vaccines Industry Drivers Table 3. Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges Table 4. Virus like Particle (VLP) Vaccines Industry Restraints Table 5. Global Virus like Particle (VLP) Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Virus like Particle (VLP) Vaccines Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Virus like Particle (VLP) Vaccines Sales Market Share by Manufacturers Table 9. Global Virus like Particle (VLP) Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Virus like Particle (VLP) Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Virus like Particle (VLP) Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Virus like Particle (VLP) Vaccines Manufacturers, Product Type & Application Table 13. Global Virus like Particle (VLP) Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Virus like Particle (VLP) Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Prophylactic Vaccine Table 17. Major Manufacturers of Therapeutic Vaccine Table 18. Global Virus like Particle (VLP) Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2026) & (K Units) Table 20. Global Virus like Particle (VLP) Vaccines Sales by Type (2027-2032) & (K Units) Table 21. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2026) Table 22. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2027-2032) Table 23. Global Virus like Particle (VLP) Vaccines Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Virus like Particle (VLP) Vaccines Revenue by Type (2021-2026) & (K Units) Table 25. Global Virus like Particle (VLP) Vaccines Revenue by Type (2027-2032) & (K Units) Table 26. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2026) Table 27. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Human Papillomavirus (HPV) Table 29. Major Manufacturers of Hepatitis E Virus (HEV) Table 30. Major Manufacturers of Hepatitis B Virus (HBV) Table 31. Major Manufacturers of Other Table 32. Global Virus like Particle (VLP) Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2026) & (K Units) Table 34. Global Virus like Particle (VLP) Vaccines Sales by Application (2027-2032) & (K Units) Table 35. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2026) Table 36. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2027-2032) Table 37. Global Virus like Particle (VLP) Vaccines Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Virus like Particle (VLP) Vaccines Revenue by Application (2021-2026) & (K Units) Table 39. Global Virus like Particle (VLP) Vaccines Revenue by Application (2027-2032) & (K Units) Table 40. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2026) Table 41. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2027-2032) Table 42. Global Virus like Particle (VLP) Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2026) & (K Units) Table 44. Global Virus like Particle (VLP) Vaccines Sales Market Share by Region (2021-2026) Table 45. Global Virus like Particle (VLP) Vaccines Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Virus like Particle (VLP) Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 49. North America Virus like Particle (VLP) Vaccines Sales by Country (2027-2032) & (K Units) Table 50. Europe Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 52. Europe Virus like Particle (VLP) Vaccines Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Virus like Particle (VLP) Vaccines Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2027-2032) & (K Units) Table 59. Global Virus like Particle (VLP) Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Virus like Particle (VLP) Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021-2026) Table 63. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2027-2032) Table 64. WuXi Biologics Company Information Table 65. WuXi Biologics Business Overview Table 66. WuXi Biologics Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio Table 68. WuXi Biologics Recent Development Table 69. Junshi Biosciences Company Information Table 70. Junshi Biosciences Business Overview Table 71. Junshi Biosciences Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio Table 73. Junshi Biosciences Recent Development Table 74. Luye Pharma Group Company Information Table 75. Luye Pharma Group Business Overview Table 76. Luye Pharma Group Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio Table 78. Luye Pharma Group Recent Development Table 79. Chengdu Kanghua Biological Products Co., Ltd. Company Information Table 80. Chengdu Kanghua Biological Products Co., Ltd. Business Overview Table 81. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 83. Chengdu Kanghua Biological Products Co., Ltd. Recent Development Table 84. Shanghai Bovax Biotechnology Co., Ltd. Company Information Table 85. Shanghai Bovax Biotechnology Co., Ltd. Business Overview Table 86. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio Table 88. Shanghai Bovax Biotechnology Co., Ltd. Recent Development Table 89. VBI Vaccines Inc Company Information Table 90. VBI Vaccines Inc Business Overview Table 91. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio Table 93. VBI Vaccines Inc Recent Development Table 94. Premas Biotech Company Information Table 95. Premas Biotech Business Overview Table 96. Premas Biotech Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio Table 98. Premas Biotech Recent Development Table 99. Creative Diagnostics Company Information Table 100. Creative Diagnostics Business Overview Table 101. Creative Diagnostics Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio Table 103. Creative Diagnostics Recent Development Table 104. Creative Biostructure Company Information Table 105. Creative Biostructure Business Overview Table 106. Creative Biostructure Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio Table 108. Creative Biostructure Recent Development Table 109. Coriolis Company Information Table 110. Coriolis Business Overview Table 111. Coriolis Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Coriolis Virus like Particle (VLP) Vaccines Product Portfolio Table 113. Coriolis Recent Development Table 114. Charles River Laboratories Company Information Table 115. Charles River Laboratories Business Overview Table 116. Charles River Laboratories Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio Table 118. Charles River Laboratories Recent Development Table 119. BioAgilytix Company Information Table 120. BioAgilytix Business Overview Table 121. BioAgilytix Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio Table 123. BioAgilytix Recent Development Table 124. AstraZeneca Group (Icosavax) Company Information Table 125. AstraZeneca Group (Icosavax) Business Overview Table 126. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio Table 128. AstraZeneca Group (Icosavax) Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Virus like Particle (VLP) Vaccines Distributors List Table 132. Virus like Particle (VLP) Vaccines Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Virus like Particle (VLP) Vaccines Product Image Figure 2. Global Virus like Particle (VLP) Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Virus like Particle (VLP) Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Virus like Particle (VLP) Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Virus like Particle (VLP) Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Prophylactic Vaccine Image Figure 9. Therapeutic Vaccine Image Figure 10. Global Virus like Particle (VLP) Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Virus like Particle (VLP) Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2032) Figure 13. Global Virus like Particle (VLP) Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Virus like Particle (VLP) Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2032) Figure 16. Human Papillomavirus (HPV) Image Figure 17. Hepatitis E Virus (HEV) Image Figure 18. Hepatitis B Virus (HBV) Image Figure 19. Other Image Figure 20. Global Virus like Particle (VLP) Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Virus like Particle (VLP) Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2032) Figure 23. Global Virus like Particle (VLP) Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Virus like Particle (VLP) Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2032) Figure 26. North America Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2032) Figure 28. U.S. Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2032) Figure 33. Germany Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2032) Figure 40. China Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales Market Share by Country (2021-2032) Figure 48. Brazil Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Virus like Particle (VLP) Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Virus like Particle (VLP) Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Virus like Particle (VLP) Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. North America Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Virus like Particle (VLP) Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Europe Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Virus like Particle (VLP) Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Virus like Particle (VLP) Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Virus like Particle (VLP) Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Prophylactic Vaccine
  • Therapeutic Vaccine
Applications
  • Human Papillomavirus (HPV)
  • Hepatitis E Virus (HEV)
  • Hepatitis B Virus (HBV)
  • Other
Companies covered
  • WuXi Biologics
  • Junshi Biosciences
  • Luye Pharma Group
  • Chengdu Kanghua Biological Products Co., Ltd.
  • Shanghai Bovax Biotechnology Co., Ltd.
  • VBI Vaccines Inc
  • Premas Biotech
  • Creative Diagnostics
  • Creative Biostructure
  • Coriolis
  • Charles River Laboratories
  • BioAgilytix
  • AstraZeneca Group (Icosavax)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Virus like Particle (VLP) Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Virus like Particle (VLP) Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Virus like Particle (VLP) Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Virus like Particle (VLP) Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Virus like Particle (VLP) Vaccines Market Dynamics
  1. 2.1 Virus like Particle (VLP) Vaccines Industry Trends
  2. 2.2 Virus like Particle (VLP) Vaccines Industry Drivers
  3. 2.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
  4. 2.4 Virus like Particle (VLP) Vaccines Industry Restraints
3 Virus like Particle (VLP) Vaccines Market by Manufacturers
  1. 3.1 Global Virus like Particle (VLP) Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Virus like Particle (VLP) Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Virus like Particle (VLP) Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Virus like Particle (VLP) Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Virus like Particle (VLP) Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Virus like Particle (VLP) Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Virus like Particle (VLP) Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Virus like Particle (VLP) Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Virus like Particle (VLP) Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Virus like Particle (VLP) Vaccines Tier 1, Tier 2, and Tier 3
4 Virus like Particle (VLP) Vaccines Market by Type
  1. 4.1 Virus like Particle (VLP) Vaccines Type Introduction
  2. 4.1.1 Prophylactic Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global Virus like Particle (VLP) Vaccines Sales by Type
  5. 4.2.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2032)
  7. 4.2.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2032)
  8. 4.3 Global Virus like Particle (VLP) Vaccines Revenue by Type
  9. 4.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2021-2032)
  11. 4.3.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2032)
5 Virus like Particle (VLP) Vaccines Market by Application
  1. 5.1 Virus like Particle (VLP) Vaccines Application Introduction
  2. 5.1.1 Human Papillomavirus (HPV)
  3. 5.1.2 Hepatitis E Virus (HEV)
  4. 5.1.3 Hepatitis B Virus (HBV)
  5. 5.1.4 Other
  6. 5.2 Global Virus like Particle (VLP) Vaccines Sales by Application
  7. 5.2.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2032)
  9. 5.2.3 Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2032)
  10. 5.3 Global Virus like Particle (VLP) Vaccines Revenue by Application
  11. 5.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2021-2032)
  13. 5.3.3 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2032)
6 Global Virus like Particle (VLP) Vaccines Sales by Region
  1. 6.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Virus like Particle (VLP) Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Virus like Particle (VLP) Vaccines Revenue by Region
  1. 7.1 Global Virus like Particle (VLP) Vaccines Revenue by Region
  2. 7.1.1 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Virus like Particle (VLP) Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Virus like Particle (VLP) Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Virus like Particle (VLP) Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Virus like Particle (VLP) Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Virus like Particle (VLP) Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Virus like Particle (VLP) Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 WuXi Biologics
  2. 8.1.1 WuXi Biologics Company Information
  3. 8.1.2 WuXi Biologics Business Overview
  4. 8.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
  6. 8.1.5 WuXi Biologics Recent Developments
  7. 8.2 Junshi Biosciences
  8. 8.2.1 Junshi Biosciences Company Information
  9. 8.2.2 Junshi Biosciences Business Overview
  10. 8.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
  12. 8.2.5 Junshi Biosciences Recent Developments
  13. 8.3 Luye Pharma Group
  14. 8.3.1 Luye Pharma Group Company Information
  15. 8.3.2 Luye Pharma Group Business Overview
  16. 8.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
  18. 8.3.5 Luye Pharma Group Recent Developments
  19. 8.4 Chengdu Kanghua Biological Products Co., Ltd.
  20. 8.4.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
  21. 8.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
  22. 8.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  24. 8.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
  25. 8.5 Shanghai Bovax Biotechnology Co., Ltd.
  26. 8.5.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
  27. 8.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
  28. 8.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
  30. 8.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
  31. 8.6 VBI Vaccines Inc
  32. 8.6.1 VBI Vaccines Inc Company Information
  33. 8.6.2 VBI Vaccines Inc Business Overview
  34. 8.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
  36. 8.6.5 VBI Vaccines Inc Recent Developments
  37. 8.7 Premas Biotech
  38. 8.7.1 Premas Biotech Company Information
  39. 8.7.2 Premas Biotech Business Overview
  40. 8.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
  42. 8.7.5 Premas Biotech Recent Developments
  43. 8.8 Creative Diagnostics
  44. 8.8.1 Creative Diagnostics Company Information
  45. 8.8.2 Creative Diagnostics Business Overview
  46. 8.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
  48. 8.8.5 Creative Diagnostics Recent Developments
  49. 8.9 Creative Biostructure
  50. 8.9.1 Creative Biostructure Company Information
  51. 8.9.2 Creative Biostructure Business Overview
  52. 8.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
  54. 8.9.5 Creative Biostructure Recent Developments
  55. 8.10 Coriolis
  56. 8.10.1 Coriolis Company Information
  57. 8.10.2 Coriolis Business Overview
  58. 8.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
  60. 8.10.5 Coriolis Recent Developments
  61. 8.11 Charles River Laboratories
  62. 8.11.1 Charles River Laboratories Company Information
  63. 8.11.2 Charles River Laboratories Business Overview
  64. 8.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
  66. 8.11.5 Charles River Laboratories Recent Developments
  67. 8.12 BioAgilytix
  68. 8.12.1 BioAgilytix Company Information
  69. 8.12.2 BioAgilytix Business Overview
  70. 8.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
  72. 8.12.5 BioAgilytix Recent Developments
  73. 8.13 AstraZeneca Group (Icosavax)
  74. 8.13.1 AstraZeneca Group (Icosavax) Company Information
  75. 8.13.2 AstraZeneca Group (Icosavax) Business Overview
  76. 8.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
  78. 8.13.5 AstraZeneca Group (Icosavax) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
  2. 9.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Virus like Particle (VLP) Vaccines Production Mode & Process
  6. 9.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Virus like Particle (VLP) Vaccines Distributors
  9. 9.2.3 Virus like Particle (VLP) Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst